Gloria Ng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gloria Ng has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ana Lucia Hincapie
Division of Pharmacy Practice & Administrative Sciences, James L. Winkle College of Pharmacy University of Cincinnati Cincinnati Ohio USA
1 shared publication - Elizabeth G. Schlosser
James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA
1 shared publication - Josiah D. Allen
Department of Precision Medicine and Genomic Health, St. Elizabeth Healthcare, Edgewood, KY 41017, USA
1 shared publication - Kendall Billman
Department of Precision Medicine & Genomic Health, St. Elizabeth Healthcare, 1 Medical Village Dr., Edgewood, KY 41017, USA
1 shared publication - Mariam Hussain
College of Health Professions, Manchester University, Fort Wayne, IN 46845, USA
1 shared publication - Mayeesha Ahmed Feldman
Department of Precision Medicine & Genomic Health, St. Elizabeth Healthcare, 1 Medical Village Dr., Edgewood, KY 41017, USA
1 shared publication
Latest Publications
- Open Access
- 29 October 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (11) , 511
Retrospective Evaluation of the Impact of SLCO1B1 Variation on Statin Effectiveness
Background: Solute carrier organic anion transporter family member 1B1 (SLCO1B1) mediates statin uptake into hepatocytes, the primary sites of cholesterol production. While the impact of SLCO1B1 variation on statin-associated muscle symptoms (SAMS) is well-documented, its role in LDL-C reduction remains understudied. This single-center, retrospective cohort study evaluated whether SLCO1B1 variation affects statin effectiveness in 213 adults. Methods: The SLCO1B1 variant rs4149056 (NM_006446.5:c.521T>C) was tested to categorize patients by their SLCO1B1 function: normal, decreased, or poor. The primary endpoint was percent change in LDL-C from baseline to follow-up (≥6 weeks post-statin initiation), with secondary endpoints of SAMS occurrence and statin adherence. Results: Overall, the average LDL-C decreased by 32% across all groups. No significant difference in LDL-C reduction was observed between SLCO1B1 phenotypes (p = 0.24). Conclusions: SLCO1B1 variation did not significantly affect LDL-C reduction, SAMS occurrence, or statin adherence. However, the retrospective design and limited adherence data in this study represent important limitations warranting prospective validation studies.
- 29 October 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (11) , 511
Open AccessRetrospective Evaluation of the Impact of SLCO1B1 Variation on Statin Effectiveness
Background: Solute carrier organic anion transporter family member 1B1 (SLCO1B1) mediates statin uptake into hepatocytes, the primary sites of cholesterol production. While the impact of SLCO1B1 variation on statin-associated muscle symptoms (SAMS) is well-documented, its role in LDL-C reduction remains understudied. This single-center, retrospective cohort study evaluated whether SLCO1B1 variation affects statin effectiveness in 213 adults. Methods: The SLCO1B1 variant rs4149056 (NM_006446.5:c.521T>C) was tested to categorize patients by their SLCO1B1 function: normal, decreased, or poor. The primary endpoint was percent change in LDL-C from baseline to follow-up (≥6 weeks post-statin initiation), with secondary endpoints of SAMS occurrence and statin adherence. Results: Overall, the average LDL-C decreased by 32% across all groups. No significant difference in LDL-C reduction was observed between SLCO1B1 phenotypes (p = 0.24). Conclusions: SLCO1B1 variation did not significantly affect LDL-C reduction, SAMS occurrence, or statin adherence. However, the retrospective design and limited adherence data in this study represent important limitations warranting prospective validation studies.